Manhattan BioSolutions to Present at the ACCESS CHINA Forum @JPM WEEK 2021

NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery of the immunoregulatory therapies for the treatment of metastatic cancers, today announced that it will be participating at the “ACCESS CHINA Forum @ JPM WEEK 2021” which will be held online on January 4th to 30th, 2021. Dr. Boris Shor, a Co-founder and CEO of MABS, will be hosting presentation on Wednesday, January 20, 2021 at 9:20PM, EST.

To access the live presentation, please use the following information:


Date: Wednesday, Janurary 20, 2021
Time: 9:20 p.m. Eastern Time (6:20 p.m. Pacific Time)
Passcode: 195754
Webinar ID: 835 7517 7814
International numbers:
If you would like to register for the event, you may purchase a free Live Day Attendee Ticket or Video on Demand Attendee Ticket here:

About Manhattan BioSolutions

Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of immunotherapies that target microbial recognition and inflammatory signaling pathways for the treatment of metastatic cancers. Manhattan BioSolutions leverages two therapeutic modalities for drug discovery: synthetic microbes – genetically engineered living drugs and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous “danger signals” released as a result of tissue injury or inflammation. The company has established partnerships with the Stony Brook University, The University at Buffalo, The University of British Columbia, INSERM and has been awarded grants by the National Institutes of Health (NIH) and the National Science Foundation (NSF).


Boris Shor, PhD
Co-Founder | CEO
Manhattan BioSolutions, Inc.